Aditya Bardia MD, MBBS, MPH

Aditya Bardia MD, MPH, completed his medical oncology fellowship at Johns Hopkins Kimmel Cancer Center. Dr. Bardia is interested in developing successful targeted and personalized therapies to improve the outcomes of patients and families afflicted with breast cancer. The accurate identification of the target is crucial for the success of targeted therapies, and Dr. Bardia is involved in the clinical development of tumor genotyping as well as circulating tumor cells (CTCs) to facilitate accurate diagnosis, therapy selection, and real-time monitoring of breast cancer.

In collaboration the CTC center and Haber lab, his research on molecular changes in CTCs in metastatic breast cancer has elucidated the role of epithelial-mesenchymal transition and provided proof-of-principle that ex-vivo CTC culture and molecular drug testing is feasible in breast cancer.Dr. Bardia is the principal investigator of clinical trials investigating the role of targeted therapy combinations for breast cancer. Dr. Bardia is the recipient of the Young Investigator Award from the ASCO Conquer Cancer Foundation.